Vermont Adopts Law Requiring Providers to Notify Patients of Unapproved Stem Cell Therapies

June 08, 2021

Vermont Governor Phil Scott signed a bill (S.22) on Monday requiring health care providers who perform stem cell therapies that are not approved by the Food and Drug Administration to provide their patients with specific notice and a disclosure form before administering an unapproved therapy. The law also requires providers to include notice that they administer unapproved stem cell products in advertisements related to the products. AABB-accredited facilities are explicitly exempt from the requirements related to notice, disclosure and advertisements.

Supporting patients’ access to safe, medically appropriate biotherapies is a core part of AABB’s mission and Advocacy Agenda. AABB will continue to collaborate with the biotherapies community to drive and support policies that ensure patient access, advance research, increase the supply and safety of biotherapies, and expand coverage of these therapies.